At Oxidien™, we are dedicated to bringing life-changing products to patients with rare kidney disorders. We create best-in-class enzyme-based pharmaceuticals through innovative research, open-minded conviction, and passionate diligence. Using sound science and expert knowledge, Oxidien™ is committed to advancing the standard of care.
Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications.
There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3 .
- IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones 1, 4, 5 . Studies suggest that one cause of IH is dietary 6, 7, 8 and that IH patients may absorb more dietary oxalate than healthy individuals 9, 10 .
- EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure. Gastrointestinal complications most often associated with increased oxalate absorption include chronic diarrhea, steatorrhea, inflammatory bowel disease(IBD), pancreatic insufficiency, biliary cirrhosis, and short-bowel syndrome. Studies show that bariatric and jejunoileal bypass surgery patients may develop EH as well 11, 12 .
OX-1 is a novel oxalate decarboxylase (OxDC) enzyme developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. OX-1 demonstrates stability in a wide pH range including very acidic environments; thus, can effectively degrade oxalate in the gastrointestinal tract, in particular the stomach.
A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Utilizing Orally Administered Oxalate Decarboxylase (OxDC) To Reduce Urinary Oxalate
In Vitro And In Vivo Safety Evaluation of Ox-1
AA-1 (also known as A0) is an oxalate decarboxylase (OxDC) enzyme originating from a fungal source. AA-1 has the potential to degrade oxalate throughout the complete gastrointestinal tract due to its extremely wide pH activity profile with activity in neutral and basic pH range.
Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate, an abstract and poster featuring research partner, Captozyme, and their A0 research.
Chief Executive Officer
BSBA, CCRP, CCRA
Director of Clinical Research
Chief Financial Officer
Ira W. Klimberg
Chief Medical Officer